MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

NCT05764161 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2025-12-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

Conditions

  • Prurigo Nodularis

Interventions

DRUG

Ruxolitinib Cream

Ruxolitinib cream 1.5% twice daily (BID) during the continuous and open label treatment period.

DRUG

Vehicle Cream

Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle-controlled period.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-12
Primary Completion
2024-12-30
Completion
2025-11-04
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Austria
  • Bulgaria
  • Canada
  • Denmark
  • France
  • Germany
  • Italy
  • Poland
  • South Korea
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05764161 on ClinicalTrials.gov